Soligenix, Inc. announced its financial results for the second quarter ended June 30, 2025, on August 14, 2025. The company reported no revenue for the quarter, consistent with the comparable period in 2024, reflecting its pre-commercial stage.
The net loss for the quarter increased to $2.7 million, or ($0.82) per share, compared to $1.6 million, or ($1.31) per share, for the second quarter of 2024. This increase in net loss was primarily due to higher research and development expenses, which rose to $1.7 million from $0.5 million, driven by costs for the Behçet's Disease Phase 2a study and the confirmatory Phase 3 CTCL trial.
As of June 30, 2025, Soligenix held approximately $5.1 million in cash and cash equivalents, with an additional $1.4 million received from its At-The-Market (ATM) facility on July 1, 2025. This cash balance is projected to provide an operating runway through the first quarter of 2026, and the company continues to explore strategic financing options.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.